TreeFrog Therapeutics, France
Maxime Feyeux was one of the first PhD students to work with pluripotent stem cells in France and on their applications in neurology, at the Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (i-Stem). During his PhD thesis, he authored in 2008 a seminal paper on pluripotent stem cells' genomic integrity, focusing on the selection of the oncogenic 20q11 mutation over prolonged culture. Maxime Feyeux continued his research in the field of PSCs at the University of Geneva, modeling Huntington's disease genetic dysregulation and investigating PSC-based therapeutic approaches. In 2014, he met Kevin Alessandri, a biophysicist specialized in cell encapsulation microfluidics. Together, they invented C-Stem™, a biomimetic technology allowing for the mass production of induced pluripotent stem cells, and their differentiation into ready-to-transplant microtissues, with unprecedented scalability and cell quality. They co-founded the biotech company TreeFrog Therapeutics in 2018, transitioning the C-Stem™ technology to GMP standards in 2022, and now developing in-house and partnered cell therapy programs in regenerative medicine and immuno-oncology.
Thursday, July 11, 2024
6:00 PM – 6:30 PM CEST